4'-C-Fluoro-uridine
- Product Name
- 4'-C-Fluoro-uridine
- CAS No.
- 1613589-24-4
- Chemical Name
- 4'-C-Fluoro-uridine
- Synonyms
- 4'-FlU;EIDD-2749;4'-Fluorouridine;4′-Fluorouridine;4'-C-Fluoro-uridine;Uridine, 4'-C-fluoro-;4'-Fluorouridine|||4'-FlU;1-[(2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione;1-[(2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
- CBNumber
- CB85822139
- Molecular Formula
- C9H11FN2O6
- Formula Weight
- 262.19
- MOL File
- 1613589-24-4.mol
4'-C-Fluoro-uridine Property
- Density
- 1.77±0.1 g/cm3(Predicted)
- solubility
- DMF: 20 mg/ml
DMSO: 10 mg/mlPBS (pH 7.2): 10 mg/ml - pka
- 9.39±0.10(Predicted)
- form
- Solid
- color
- Off-white to yellow
- InChI
- InChI=1S/C9H11FN2O6/c10-9(3-13)6(16)5(15)7(18-9)12-2-1-4(14)11-8(12)17/h1-2,5-7,13,15-16H,3H2,(H,11,14,17)/t5-,6+,7-,9-/m1/s1
- InChIKey
- RDCYLPRXPILMRP-JVZYCSMKSA-N
- SMILES
- OC[C@@]1(F)O[C@@H](N2C=CC(=O)NC2=O)[C@H](O)[C@@H]1O
4'-C-Fluoro-uridine Chemical Properties,Usage,Production
Uses
EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses[1][2][3].
in vivo
EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner[1].
EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo[2].
| Animal Model: | Balb/cJ mice (RSV infection model)[1]. |
| Dosage: | 0.2, 1, 5 mg/kg |
| Administration: | Oral administration; single daily for 4 days |
| Result: | Resulted in a statistically significant reduction in lung virus load. |
References
[1] Sourimant J, et al. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375(6577):161-167. DOI:10.1126/science.abj5508
[2] Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410.
[3] George R. Painter, et al. 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1.
4'-C-Fluoro-uridine Preparation Products And Raw materials
Raw materials
Preparation Products
4'-C-Fluoro-uridine Suppliers
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 52923
- Advantage
- 58